Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Shawn O'Connor

Shawn O'Connor

Chief Executive Officer, Simulations Plus

Appears in 1 story

Notable Quotes

O'Connor cited funding uncertainty, drug-pricing pressure, and possible tariffs as headwinds pushing pharma clients to cut budgets and cancel projects.

Stories

Altaris takes drug-simulation software maker Simulations Plus private

Money Moves

Leading the company through the sale to Altaris

Simulations Plus agreed on June 16, 2026 to be taken private by Altaris for $18.50 a share, or about $375 million total. Shareholders get a 26% premium over the prior 60-day average. Altaris plans to fold the company into Chemical Computing Group, a molecular-design firm it already owns.

Updated Jun 17